In 2016, the World Health Organization (WHO) classification of gliomas used molecular parameters including isocitrate dehydrogenase 1 and 2 (IDH1 and IDH2) mutations and 1p/19q codeletion status in addition to histopathological criteria.7 The gene discussed is IDH2; the disease is central nervous system cancer.